UNOG-NEWS WHO COVID-19- Treatments - Remdesivir 20NOV2020
/
3:08
/
MP4
/
231.7 MB

Edited News | WHO

UNOG-NEWS WHO COVID-19- Treatments - Remdesivir 20NOV2020

COVID-19: UN health agency issues conditional advice against using remdesivir

Patients with COVID-19 should not be given the antiviral drug remdesivir “regardless of disease severity”, the UN World Health Organization (WHO) said on Friday.

Nonetheless, describing its recommendation as “conditional”, as opposed to “strong”, WHO stressed that data from a global trial on the efficacy of remdesivir was inconclusive, and that further trials should continue into its use for more vulnerable patients.

“We recommend a conditional recommendation – I want to highlight that - against the use of remdesivir in hospitalised patients with COVID-19 regardless of disease severity,” said Dr Janet Diaz, Head of Clinical Care at WHO, during a virtual press conference in Geneva.

According to data from the WHO-led Solidarity trial which was then examined by a panel of international experts behind the recommendation, “possibly remdesivir can lead to 29 fewer deaths per 1,000 patients or up to 11 more deaths per 1000 patients”, Dr Diaz said. “So you can see that …the confidence interval are relatively large…there was no evidence that there was any important effect on mortality, on the need for mechanical ventilation or the time to clinical improvement.”

But this did “not prove” that the antiviral “had no benefit at all”, Dr Diaz insisted. “There could still be potential small benefit, maybe in a health sub-group which is why the panel also recommended continued trials, continued enrolment into clinical trials.”

The WHO official explained that this might be “severe patients versus critical patients” or whether the antiviral is used “early versus late”.

Dr Bram Rochwerg, who was among the experts advising WHO, noted that there would likely be regional “variations” in the use of remdesivir.

While a minority of people will still choose to use it, the majority would not, based on the available data, he said.

“There may be groups (who might benefit) and the data was a bit more of a close call, so that’s why we felt strongly that trials need to continue using remdesivir and studying remdesivir and looking to see if there are specific groups that might, that might benefit,” he said. “We were very explicit that we do believe that these studies need to continue (and) Solidarity is continuing.”

Although the remdesivir development mirrors similar attempts to use other antivirals against the new coronavirus, Dr Diaz said there was no reason to lose hope in the fight against COVID-19.

“I do think there is a tremendous global effort to investigate treatments. You know, I think a lot of interest was done upfront with the repurposed of drugs, repurposed antivirals, you know we saw that with other repurposed drugs such as hydroxychloroquine, lopinavir, and there was a big push to try to test these and they’ve been tested and unfortunately, we just haven’t, you know, the results haven’t been as promising as we had hoped. But I don’t want to forget that we do have one lifesaving drug and even though it’s a repurposed old, old drug dexamethasone, a corticosteroid, we do know that that does reduce mortality, save lives of patient with severe and critical so there is something.”

Latest data from WHO indicates that eight in 10 people infected with COVID report mild symptoms, Dr Diaz said.

“Since the beginning (of the pandemic)…about 80 per cent of people have, you know, mild disease, a proportion maybe moderate disease and then only a small proportion, a smaller proportion, 20 per cent go on to develop severe or critical disease, and critical disease is a small, small portion, it’s five per cent or less, and that is…and that seems to be kind of consistent I think through the literature so most patients do have, if they have mild disease, self-limiting disease, they get better on their own, their immune system kicks in and they get better.”

Nonetheless, there are reports of more “persistent longer-term symptoms”, Dr Diaz noted. “So even though they don’t get severe disease there can be some persistent symptoms that lasts longer than one would have hoped for.”

  1. SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “We recommend a conditional recommendation - so I want to highlight that, it’s a conditional recommendation - against the use of remdesivir in hospitalized patients - with COVID-19, regardless of disease severity.”
  2. SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “Possibly remdesivir can lead to 29 fewer deaths par 1,000 patients or up to 11 more deaths per 1,000 patients so you can see that this is, the confidence interval is a little bit large.”
  3. SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “It was not clear that, there was no evidence, that there was any important effect on mortality, on the need for mechanic ventilation or the time to clinical improvement.”
  4. SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “This did not prove that remdesivir does not have a benefit at all and that’s why it is a conditional recommendation, there can still be potential small benefit, maybe in a health sub-group, which is why the panel also recommended continued trials, continued enrolment into clinical trials.”
  5. SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “You know, is there a sub-group that may benefit more – such as severe patients versus critical patients. Is there a timing in disease that may benefit more - such as early versus late - and those are all considerations that are in the guidelines.”
  6. SOUNDBITE (English) — Dr Bram Rochwerg, practising ITU clinician and expert adviser for WHO-led Solidarity Trial: “There may be groups and the data was a bit more of a close call, so that’s why we felt strongly that trials need to continue using remdesivir and studying remdesivir and looking to see if there are specific groups that might, that might benefit. And as she said, we were very explicit that we do believe that these studies need to continue, Solidarity is continuing, so.”
  7. SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “I do think there is a tremendous global effort to investigate treatments. You know, I think a lot of interest was done upfront with the repurposed of drugs, repurposed antivirals, you know we saw that with other repurposed drugs such as hydroxychloroquine, lopinavir, and there was a big push to try to test these and they’ve been tested and unfortunately, we just haven’t, you know, the results haven’t been as promising as we had hoped. But I don’t want to, I don’t want to forget that we do have one lifesaving drug and even though it’s a repurposed old, old drug dexamethasone, a corticosteroid, we do know that that does reduce mortality, save lives of patient with severe and critical so there is something.”
  8. SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “Since the beginning, is that about 80 per cent of people have, you know, mild disease, a proportion maybe moderate disease and then only a small proportion, a smaller proportion, 20 per cent go on to develop severe or critical disease, and critical disease is a small, small portion, it’s five per cent or less, and that is…and that seems to be kind of consistent I think through the literature so most patients do have, if they have mild disease, self-limiting disease, they get better on their own, their immune system kicks in and they get better.”
  9. SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “We do know that even patients with mild disease may have persistent longer-term symptoms. And that has been now described; so even though they don’t get severe disease there can be some persistent symptoms that lasts longer than one would have hoped for.”

Similar Stories

UN Human Rights Spokesperson Jeremy Laurence on attacks around aid sites in Gaza

1

1

1

Edited News | OHCHR , UNOG

UN Human Rights Spokesperson Jeremy Laurence on attacks around aid sites in Gaza ENG FRA

“Deadly attacks on distraught civilians trying to access the paltry amounts of food aid in Gaza, are unconscionable. For a third day running, people were killed around an aid distribution site run by the Gaza Humanitarian Foundation. This morning, we have received information that dozens more people were killed and injured,” Jeremy Laurence UN Human Rights spokesperson said at the biweekly press briefing in Geneva.

Gaza aid update - OCHA 30 May 2025

1

1

1

Edited News | OCHA

Gaza aid update - OCHA 30 May 2025 ENG FRA

Gaza ‘hungriest place on earth’ with aid stymied – UN humanitarians

Starving Gazans continue to be deprived of aid as international relief efforts are being severely constrained by the Israeli authorities, the UN humanitarian affairs coordination office OCHA said on Friday.

Gaza humanitarian update - OCHA, UNRWA

1

1

1

Edited News | OCHA , UNRWA

Gaza humanitarian update - OCHA, UNRWA ENG FRA

As a controversial United States and Israel-backed aid distribution plan gets underway in Gaza, the UN called on Tuesday for an “immediate surge” of its own pre-positioned supplies to help prevent starvation.

Uganda UN Human Rights Spokesperson Ravina Shamdasani  urges president to reject bill allowing trials of civilians in military courts

1

1

1

Edited News | OHCHR

Uganda UN Human Rights Spokesperson Ravina Shamdasani urges president to reject bill allowing trials of civilians in military courts ENG FRA

UN Human Rights Office Spokesperson Ravina Shamdasani today urged Ugandan President Yoweri Museveni to reject a bill that was recently endorsed by parliament allowing trials of civilians in military courts. The Uganda People’s Defence Forces Amendment Bill 2025, which was passed on 20 May and now awaits presidential signature to become law, among others broadens the jurisdiction of military courts, authorising them to try a wide range of offences against civilians.

UN Human Rights Office spokesperson Seif Magango: South Sudan: UN human rights chief decries escalating hostilities, arbitrary arrests and hate speech

1

1

1

Edited News | OHCHR

UN Human Rights Office spokesperson Seif Magango: South Sudan: UN human rights chief decries escalating hostilities, arbitrary arrests and hate speech ENG FRA

UN Human Rights Office spokesperson Seif Magango today warned of a further deterioration in the human rights situation in South Sudan at the bi-weekly briefing in Geneva.

Syria humanitarian update OCHA - WHO 23 May 2025

1

1

1

Edited News | OCHA , WHO

Syria humanitarian update OCHA - WHO 23 May 2025 ENG FRA

Syria: ‘Staggering’ needs amid insecurity, health care crisis  - UN humanitarians

Millions of people in Syria continue to face mortal danger from unexploded munitions, disease and malnutrition and urgent support is required, UN humanitarians said on Friday.

Gaza health update - UNRWA - OCHA - WHO

1

1

1

Edited News | UNRWA , OCHA , WHO

Gaza health update - UNRWA - OCHA - WHO ENG FRA

UN life-saving aid allowed to trickle into Gaza as civilian needs mount

Amid calls for more humanitarian trucks to enter the food and medicine-deprived Palestinian enclave of Gaza, UN humanitarians have received permission from Israel for “around 100” more aid trucks to cross into the Strip after only five were let in yesterday,  But the scale of relief efforts allowed remains entirely insufficient to meet the urgent needs of people there, humanitarian workers say.

Press vests becoming a target - war reporter Christina Assi

1

1

1

Edited News

Press vests becoming a target - war reporter Christina Assi ENG FRA

A war reporter from Lebanon who lost a limb in the line of duty is calling for an end to impunity for attacks against journalists.

ITU 160th Anniversary - 17 May 2025

1

1

1

Edited News | ITU

ITU 160th Anniversary - 17 May 2025 ENG FRA

The International Telecommunication Union (ITU) commemorated 160 years dedicated to connecting the world on Saturday, 17 May in Geneva, Switzerland, during the annual World Telecommunication and Information Society Day.

Gaza humanitarian update – WHO, OCHA 16 May 2025

1

1

1

Edited News | WHO , OCHA

Gaza humanitarian update – WHO, OCHA 16 May 2025 ENG FRA

Gazans ‘in terror’ after another night of deadly strikes and siege

Amid reports that Israeli strikes across Gaza into Friday killed at least 64 people, aid teams once again pushed back strongly at allegations that aid is being diverted to Hamas and pleaded for the blockade to end.

UN Human Rights raises human rights concerns about deportations from the United States of America

1

1

1

Edited News | OHCHR , UNOG

UN Human Rights raises human rights concerns about deportations from the United States of America ENG FRA

Deportations over recent months of large numbers of non-nationals from the United States of America, especially to countries other than those of their origin, raise a number of human rights concerns, the UN Human Rights Chief Volker Türk warned on Tuesday.   

Gaza health update - WHO

1

1

1

Edited News | WHO

Gaza health update - WHO ENG FRA

Gaza: Over 50 child malnutrition deaths amid aid blockade; entire generation will be ‘permanently affected’ - WHO

In the aid desert of Gaza, malnourished children are dying while survivors can expect a lifetime of dire health problems, the UN World Health Organization (WHO) said on Tuesday.